Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Biogen has a 1-year low of $128.51 and a 1-year high of $238.00. Biogen ( NASDAQ:BIIB – Get Free Report ) last announced its quarterly earnings results on Wednesday, February 12th.

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

The firm owned 4,179 shares of the biotechnology company’s stock after acquiring an additional 423 shares during the period. Savant Capital LLC’s holdings in Biogen were worth $639,000 at the ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

In 2025, 4K resolution is the standard for high-quality media, and compared to older high-definition (HD) and standard definition (SD) resolutions, it's a big improvement. Many of the best TVs ...

Shares of Biogen Inc. BIIB rallied 2.60% to $140.64 Friday, on what proved to be an all-around grim trading session for the ...

Biogen reported this week that sales of the drug reached $67 million in the third quarter – including $39 million in the US – which fell short of the company's expectations. It said the ...

Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer's therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in the US ...